open access

Vol 10, No 3 (2006)
Prace oryginalne
Published online: 2006-06-05
Get Citation

Frequency of Gly972Arg polymorphism of the insulin receptor substrate 1 (IRS-1) gene in essential hypertension

Joanna Dziwura, Agnieszka Bińczak-Kuleta, Krystyna Widecka
Nadciśnienie tętnicze 2006;10(3):174-179.

open access

Vol 10, No 3 (2006)
Prace oryginalne
Published online: 2006-06-05

Abstract

Introduction Difficulties in studies on the genetic background of arterial hypertension are compounded when hypertension is part of the complex polymetabolic syndrome together with obesity, type 2 diabetes, and dyslipidemia. Atherogenicity in this case is fuelled by insulin resistance present in some 50% of patients with hypertension. The present study was undertaken to determine the frequency of Gly972Arg polymorphism of the cytoplasmic insulin receptor substrate-1 (IRS-1) gene in a well-defined, homogenous group of patients with essential hypertension.
Material and methods The study group comprised 115 nonobese (BMI 24.72 ± 1.93 kg/m2) patients, aged 27.48 ± 5.15 years, with essential and uncomplicated arterial hypertension, while 46 healthy persons aged 28.0 ± 4.39 years (BMI 22.6 ± 2.16 kg/m2) formed the control group. There were no cases of diabetes or dyslipidemia in the groups. A single sample of 5 ml venous blood was drawn and genomic DNA was isolated for genotyping with the polymerase chain reaction as described by Yamade et al.
Results The GA genotype was disclosed in 16 (13.9%) patients and in just 2 controls (4.3%), one of them (2.2%) being AA homozygote. The χ2 test did not disclose significant differences between both groups in the distribution of genotypes.
Conclusion The distribution of Gly972Arg polymorphism of the IRS-1 gene appears to be similar in hypertensives and normotensives suggesting that this polymorphism is not directly involved in the pathogenesis of arterial hypertension.

Abstract

Introduction Difficulties in studies on the genetic background of arterial hypertension are compounded when hypertension is part of the complex polymetabolic syndrome together with obesity, type 2 diabetes, and dyslipidemia. Atherogenicity in this case is fuelled by insulin resistance present in some 50% of patients with hypertension. The present study was undertaken to determine the frequency of Gly972Arg polymorphism of the cytoplasmic insulin receptor substrate-1 (IRS-1) gene in a well-defined, homogenous group of patients with essential hypertension.
Material and methods The study group comprised 115 nonobese (BMI 24.72 ± 1.93 kg/m2) patients, aged 27.48 ± 5.15 years, with essential and uncomplicated arterial hypertension, while 46 healthy persons aged 28.0 ± 4.39 years (BMI 22.6 ± 2.16 kg/m2) formed the control group. There were no cases of diabetes or dyslipidemia in the groups. A single sample of 5 ml venous blood was drawn and genomic DNA was isolated for genotyping with the polymerase chain reaction as described by Yamade et al.
Results The GA genotype was disclosed in 16 (13.9%) patients and in just 2 controls (4.3%), one of them (2.2%) being AA homozygote. The χ2 test did not disclose significant differences between both groups in the distribution of genotypes.
Conclusion The distribution of Gly972Arg polymorphism of the IRS-1 gene appears to be similar in hypertensives and normotensives suggesting that this polymorphism is not directly involved in the pathogenesis of arterial hypertension.
Get Citation

Keywords

arterial hypertension; insulin resistance; Gly972Arg polymorphism of the insulin receptor substrate-1 gene

About this article
Title

Frequency of Gly972Arg polymorphism of the insulin receptor substrate 1 (IRS-1) gene in essential hypertension

Journal

Arterial Hypertension

Issue

Vol 10, No 3 (2006)

Pages

174-179

Published online

2006-06-05

Bibliographic record

Nadciśnienie tętnicze 2006;10(3):174-179.

Keywords

arterial hypertension
insulin resistance
Gly972Arg polymorphism of the insulin receptor substrate-1 gene

Authors

Joanna Dziwura
Agnieszka Bińczak-Kuleta
Krystyna Widecka

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

By "Via Medica sp. z o.o." sp.k., ul. Świętokrzyska 73, 80–180 Gdańsk

tel.:+48 58 320 94 94, faks:+48 58 320 94 60, e-mail: viamedica@viamedica.pl